fbpx
Medical Innovation Exchange

Axcella misses primary endpoint in long COVID trial but plots path to market based on fatigue scores

https://www.fiercebiotech.com/biotech/axcella-misses-primary-endpoint-long-covid-trial-plots-path-market-based-fatigue-scores

Leave a Comment

Your email address will not be published.

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.